Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jeff Wiezorek"'
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Autor:
Sattva S. Neelapu, John Kuruvilla, Liting Zhu, Brian K. Link, Sami Boussetta, Umar Farooq, Annette E. Hay, Eric Van Den Neste, William Y. Go, James R. Cerhan, Christian Gisselbrecht, Jeff Wiezorek, Lei Feng, Jason R. Westin, Matthew J. Maurer, Lynn Navale, Michael Crump
Publikováno v:
Blood. 130:1800-1808
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5640f1075adb5ba8149b8cac20757111
https://doi.org/10.1182/blood-2017-03-769620
https://doi.org/10.1182/blood-2017-03-769620
Autor:
Jeff Wiezorek, Sattva S. Neelapu, Chitra Hosing, William Y. Go, Adrian Bot, Jeff Aycock, Lihua E. Budde, Julio C. Chavez, Nancy L. Bartlett, Meg Elias, Yizhou Jiang, Frederick L. Locke, Tanya Siddiqi, Armin Ghobadi, Allen Xue, John M. Rossi
Publikováno v:
Molecular Therapy. 25:285-295
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c408e1ab4745e22773572b697ab953
https://doi.org/10.1016/j.ymthe.2016.10.020
https://doi.org/10.1016/j.ymthe.2016.10.020
Autor:
Armin Ghobadi, Ira Braunschweig, Sattva S. Neelapu, David Z. Chang, Abhinav Deol, Andre Goy, Patrick J. Stiff, Thomas E. Witzig, Javier Munoz, Nancy L. Bartlett, David B. Miklos, Jason R. Westin, Meg Elias, Ian W. Flinn, Januario E. Castro, John M. Timmerman, Tanya Siddiqi, Frederick L. Locke, Eric D. Jacobsen, Olalekan O. Oluwole, Peter A. McSweeney, William Y. Go, Yi Lin, Jeff Wiezorek, Lazaros J. Lekakis, Ronald Levy, Umar Farooq, Caron A. Jacobson, Jeff Aycock, Mitchell R. Smith, Julio C. Chavez, Irit Avivi, Yizhou Jiang, Jonathan W. Friedberg, Krishna V. Komanduri, John J. Rossi, Patrick M. Reagan, Brian T. Hill, Lynn Navale, Adrian Bot
Publikováno v:
The New England journal of medicine, vol 377, iss 26
BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efafe559a0e95eb63e836f7cfacc621e
https://pubmed.ncbi.nlm.nih.gov/31014778
https://pubmed.ncbi.nlm.nih.gov/31014778
Autor:
Yizhou Jiang, Olalekan O. Oluwole, Lynn Navale, Adrian Bot, Ira Braunschweig, Frederick L. Locke, Jeff Aycock, Meg Elias, John J. Rossi, Jeff Wiezorek, David B. Miklos, Lazaros J. Lekakis, Tanya Siddiqi, Nancy L. Bartlett, Patrick M. Reagan, Yi Lin, Sattva S. Neelapu, William Y. Go, Eric N. Jacobsen, John M. Timmerman
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S74-S75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48b7c35767ee8fb7faaa0ae936d5c320
https://doi.org/10.1016/j.bbmt.2017.12.644
https://doi.org/10.1016/j.bbmt.2017.12.644
Autor:
Jeff Aycock, Michelle Hemiston, Shanna Stout, Armen Mardiros, André Baruchel, Rajul K. Jain, Yizhou Jiang, Van Huynh, Alan S. Wayne, Rob Pieters, Jeff Wiezorek, Daniel W. Lee, Rupert Handgretinger, Lynn Navale, Tobias Feuchtinger, Yves Bertrand, John J. Rossi, Patrick Brown, Gérard Michel
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S252-S253
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b8cdea05bf4f205557e92db06d5a3bb
https://doi.org/10.1016/j.clml.2017.07.013
https://doi.org/10.1016/j.clml.2017.07.013
Autor:
Tanya Siddiqi, Sattva S. Neelapu, Janice Nagatani, Daniel H. Ryan, Lynn Navale, Ira Braunschweig, Adrian Bot, Xiao Zhang, John M. Timmerman, Lazaros J. Lekakis, Caron A. Jacobson, Olalekan O. Oluwole, Marika Sherman, Yi Lin, Frederick L. Locke, John J. Rossi, Xiaodong Xue, David B. Miklos, William Y. Go, Armin Ghobadi, Patrick M. Reagan, Jeff Wiezorek
Publikováno v:
Cancer Research. 77:CT020-CT020
Introduction: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy. ZUMA-1 is a multicenter registrational trial of axi-cel in patients with refractory, aggressive B-cell non-Hodgkin lymphoma. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2917876f3d253eeb46eaac3329ceed4b
https://doi.org/10.1158/1538-7445.am2017-ct020
https://doi.org/10.1158/1538-7445.am2017-ct020
Autor:
Eric D. Jacobsen, Nancy L. Bartlett, Ian W. Flinn, Julio C. Chavez, Krishna V. Komanduri, Peter A. McSweeney, Lazaros J. Lekakis, Jonathan W. Friedberg, Patrick J. Stiff, John M. Timmerman, Meg Elias, Abhinav Deol, Sattva S. Neelapu, Javier Munoz, Andre Goy, Olalekan O. Oluwole, Armin Ghobadi, Irit Avivi, Umar Farooq, Patrick M. Reagan, Januario E. Castro, Frederick L. Locke, Yi Lin, William Y. Go, Caron A. Jacobson, John M. Rossi, Jeff Wiezorek, Lynn Navale, Adrian Bot, Yizhou Jiang, Ira Braunschweig, Jason R. Westin, Jeff Aycock, Mitchell R. Smith, Tanya Siddiqi, David B. Miklos, Ronald Levy
Publikováno v:
Blood. 128:LBA-6
Background: Patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL) have poor outcomes with currently available therapies, with a complete response (CR) rate of 8%, a partial response (PR) rate of 18%, and median overall survival (OS) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86deac3c9c1ec1255352ead7645e6afc
https://doi.org/10.1182/blood.v128.22.lba-6.lba-6
https://doi.org/10.1182/blood.v128.22.lba-6.lba-6
Autor:
Jason R. Westin, Nancy L. Bartlett, Caron A. Jacobson, John M. Rossi, Sattva S. Neelapu, Alex F. Herrera, Adrian Bot, Ann S. LaCasce, Jeff Aycock, Armin Ghobadi, Julio C. Chavez, Jeff Wiezorek, Frederick L. Locke, Yizhou Jiang, Meg Elias, Tanya Siddiqi, William Y. Go
Publikováno v:
Blood. 128:998-998
Background: ZUMA-1 is a phase 1-2 multicenter, open-label study evaluating the safety and efficacy of KTE-C19 in patients with refractory aggressive B-cell non-Hodgkin lymphoma. In phase 1, KTE-C19 demonstrated ongoing complete remissions with a tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33e9006fea078bbf09177984832fdeb1
https://doi.org/10.1182/blood.v128.22.998.998
https://doi.org/10.1182/blood.v128.22.998.998
Autor:
William G. Wierda, Marianna Sabatino, John M. Rossi, Leonard S. Sender, Alan S. Wayne, Andrew C. Dietz, Jeff Wiezorek, Shanna Stout, Jeff Aycock, Yizhou Jiang, Rupert Handgretinger, Joseph Rosenthal, Rajul K. Jain, Van Huynh, Lia Gore, Gary J. Schiller, Patrick Brown, Marie José Kersten, Nicola Gökbuget, Bijal D. Shah, Januario E. Castro, Lynn Navale, Daniel W. Lee, Adrian Bot
Publikováno v:
Blood. 128:2803-2803
Background: Acute lymphoblastic leukemia (ALL) exhibits a bimodal age distribution with 60% of cases occurring in children and adolescents (45 y; Howlader SEER Cancer Statistics 2015). Most adults and 15-20% of children will relapse following initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccbbc76da3d60fdd0f6ee2cd0eefffa5
https://doi.org/10.1182/blood.v128.22.2803.2803
https://doi.org/10.1182/blood.v128.22.2803.2803
Autor:
Amanda F. Cashen, Julio C. Chavez, Lynn Navale, Adrian Bot, Jeff Wiezorek, Sattva S. Neelapu, Yizhou Jiang, Jeff Aycock, Tanya Siddiqi, Meg Elias, John J. Rossi, Lihua E. Budde, Nancy L. Bartlett, William Y. Go, Chitra Hosing, Frederick L. Locke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:S102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abb8eef83b7cfacf3c21b4f1844f293a
https://doi.org/10.1016/j.clml.2016.07.148
https://doi.org/10.1016/j.clml.2016.07.148